Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Etrolizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms HICKORY
- Sponsors Roche
- 01 Sep 2016 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
- 01 Sep 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.
- 31 Dec 2015 Planned End Date changed from 1 Jan 2019 to 1 Dec 2018 as reported by ClinicalTrials.gov record.